Guangdong Hybribio Biotech financials at a glance

+ Portfolio

The revenue of Guangdong Hybribio Biotech is reported as 1.10445 billion Yuan Renminbi in the fiscal year 2023. The earnings were 0.2 Yuan Renminbi per share in 2023, which was 92.4 lower than 2022. And about -0.06572 billion Yuan Renminbi are reported as free cash flow in the financials of Guangdong Hybribio Biotech 2023. Dividends of 0 Yuan Renminbi per share were paid to shareholders of Guangdong Hybribio Biotech stock SZSE:300639 in fiscal 2023.

¥1.10B

Revenue

¥0.20

Earnings Per Share

61.03%

Gross Margin %

¥0.00M

Free Cash Flow

Revenue

1,104.45

Earnings Per Share

0.20

Gross Margin %

61.03

Free Cash Flow

0.00

Financials

Year	Year	TTM	2023	2022	2016
Rev.	Revenue	N/A	¥1.10B	¥5.60B	¥0.00M
GM %	Gross Margin %	64.02%	61.03%	67.63%	85.67%
OM	Operating Margin	23.43%	0.89%	43.21%	20.41%
EPS	Earnings Per Share	¥0.62	¥0.20	¥2.63	¥0.16
Div.	Dividends	N/A	¥0.00	¥0.00	¥0.00
PR %	Payout Ratio %	0	0	0	0
Sha.	Shares	N/AM	294.06M	651.68M	456.14M
OCF	Operating Cash Flow	N/A	¥319.60M	¥1.31B	¥0.00M
FCF	Free Cash Flow	N/A	¥-65.72M	¥574.85M	¥0.00M
FCFS	Free Cash Flow Per Share	¥0.30	¥-0.12	¥0.87	¥-0.03

Guangdong Hybribio Biotech financials at a glance

Financials

Discover